Angiotech receives favourable decision from the European Patent Office



    EPO Rejects Attempted Intervention and Appeals of Conor Medsystems and
    Sahajanand Medical

    VANCOUVER, March 15 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:  
ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company,
announced a favourable decision regarding its Hunter Patent from the European
Patent Office (EPO) in Munich, Germany.
    The EPO's Technical Board of Appeal rejected the attempt by Conor
Medsystems Inc. and Sahajanand Medical Technologies Pvt. Ltd. to intervene and
appeal an earlier decision by the Opposition Division of the European Patent
Office, which upheld the Hunter patent. The decision found that these appeals
were "inadmissible."
    "We are pleased with the EPO's decision, and Angiotech views this outcome
as yet another confirmation of the strength and validity of our patent
portfolio," said Dr. William Hunter, President and CEO of Angiotech.
    "We continue to have great success defending our intellectual property,
and we remain committed to vigorously protect our important proprietary
technologies in jurisdictions around the world," added Dr. Hunter.

    Note on Forward Looking Statements:

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2007 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research development and
product and drug development. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements.
    Many such risks, uncertainties and other factors are taken into account
as part of our assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in drug
discovery and clinical development processes; decisions, and the timing of
decisions, made by health regulatory agencies regarding approval of our
technology and products; the requirement for substantial funding to conduct
research and development and to expand commercialization activities or
consummate acquisitions; and any other factors that may affect performance. In
addition, our business is subject to certain operating risks that may cause
the actual results expressed or implied by the forward-looking statements in
this report to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete preclinical and clinical development of our
products; changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection resulting
from third party challenges to our patents; commercialization limitations
imposed by patents owned or controlled by third parties; our ability to obtain
rights to technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce timely patent
and other intellectual property protection for our technology and products;
the ability to enter into, and to maintain, corporate alliances relating to
the development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; our ability to continue to integrate into
our business the operations of American Medical Instruments Holdings, Inc.
("AMI"); our ability to achieve the operational and other synergies and the
other commercial or financial benefits expected as a result of the acquisition
of AMI; and any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory authorities
or the SEC.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with 17 facilities in 6 countries and over 1,500
dedicated employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find out more
about Angiotech (NASDAQ:   ANPI, TSX: ANP), please visit our website at
www.angiotech.com.





For further information:

For further information: Janet Craig, VP, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6933,
jcraig@angio.com; Jodi Regts, Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,
jregts@angio.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890